Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2014

01.12.2014 | short review

ASCO 2014: highlights in breast cancer

verfasst von: Rupert Bartsch, Elisabeth Bergen, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

While in general, not immediately praxis changing, results of various relevant clinical trials were presented at the 2014 ASCO Annual Meeting. Indeed, the ALTTO study provided first (albeit negative) data on the activity of dual Her2 inhibition with trastuzumab and lapatinib (either sequentially or concomitantly) in the adjuvant setting, while a combined analysis of the SOFT and TEXT studies suggested, for the first time, that a combination of ovarian function suppression (OFS) plus exemestane might be superior to OFS plus tamoxifen in premenopausal early breast cancer patients. Results of the POEMS trial investigating the role of the gonadotropin-releasing hormone-analog goserelin in the prevention of chemotherapy-induced amenorrhea led to lengthy debates, as the trial reported a survival benefit in hormone-receptor-negative breast cancer patients receiving goserelin. A subgroup analysis of German Breast Group trial GeparSixto as well as several other phase II trials again emphasized the role of carboplatin in neoadjuvant therapy of triple-negative breast cancer patients. These and other studies will be reviewed within this article.
Literatur
1.
Zurück zum Zitat Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–40.PubMedCrossRef Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–40.PubMedCrossRef
2.
Zurück zum Zitat Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.PubMedCrossRef Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.PubMedCrossRef
3.
Zurück zum Zitat Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.PubMedCrossRef Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.PubMedCrossRef
4.
Zurück zum Zitat Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone, trastuzumab alone, their sequence, or their combination in the adjuvant treatment of HER2-positive early breast cancer. J Clin Oncol. 2014;32(Suppl. 18):LBA4. Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone, trastuzumab alone, their sequence, or their combination in the adjuvant treatment of HER2-positive early breast cancer. J Clin Oncol. 2014;32(Suppl. 18):LBA4.
5.
Zurück zum Zitat Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–18.PubMedCrossRef Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–18.PubMedCrossRef
6.
Zurück zum Zitat Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(22):679–91.PubMedCrossRef Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(22):679–91.PubMedCrossRef
7.
Zurück zum Zitat Moore HCF, Unger JM, Phillips K-A, et al. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: an international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). J Clin Oncol. 2014;32(Suppl. 18):LBA505. Moore HCF, Unger JM, Phillips K-A, et al. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: an international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). J Clin Oncol. 2014;32(Suppl. 18):LBA505.
8.
Zurück zum Zitat Coudert BP, Pierga JY, Mouret-Reynier MA, et al. AVATAXHER: an open-label, randomized, multicenter study investigating the addition of bevacizumab (B) to neoadjuvant trastuzumab (T) plus docetaxel (D) in patients with early stage HER2-positive breast cancer (HER2 + BC) stratified according to PET change after one therapy cycle. J Clin Oncol. 2014;32(Suppl. 18):Abstr. 507. Coudert BP, Pierga JY, Mouret-Reynier MA, et al. AVATAXHER: an open-label, randomized, multicenter study investigating the addition of bevacizumab (B) to neoadjuvant trastuzumab (T) plus docetaxel (D) in patients with early stage HER2-positive breast cancer (HER2 + BC) stratified according to PET change after one therapy cycle. J Clin Oncol. 2014;32(Suppl. 18):Abstr. 507.
9.
Zurück zum Zitat Tamura K, Hashimoto J, Tsuda H, et al. Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. J Clin Oncol. 2014;32(Suppl. 18):Abstr. 1017. Tamura K, Hashimoto J, Tsuda H, et al. Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. J Clin Oncol. 2014;32(Suppl. 18):Abstr. 1017.
10.
Zurück zum Zitat Sharma P, Stecklein SR, Kimler BF, et al. Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and BRCA-associated triple-negative breast cancer (TNBC). J Clin Oncol. 2014;32(Suppl. 18):Abstr. 1022. Sharma P, Stecklein SR, Kimler BF, et al. Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and BRCA-associated triple-negative breast cancer (TNBC). J Clin Oncol. 2014;32(Suppl. 18):Abstr. 1022.
11.
Zurück zum Zitat Earl HM, Hiller L, Blenkinsop C, et al. ARTemis: a randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer—primary endpoint, pathological complete response (pCR). J Clin Oncol. 2014;32(Suppl. 18):Abstr. 1014. Earl HM, Hiller L, Blenkinsop C, et al. ARTemis: a randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer—primary endpoint, pathological complete response (pCR). J Clin Oncol. 2014;32(Suppl. 18):Abstr. 1014.
12.
Zurück zum Zitat Von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299–309. Von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299–309.
13.
Zurück zum Zitat Von Minckwitz G, Hahnen E, Fasching PA, et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. J Clin Oncol. 2014;32(Suppl. 18):Abstr. 1005. Von Minckwitz G, Hahnen E, Fasching PA, et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. J Clin Oncol. 2014;32(Suppl. 18):Abstr. 1005.
Metadaten
Titel
ASCO 2014: highlights in breast cancer
verfasst von
Rupert Bartsch
Elisabeth Bergen, MD
Publikationsdatum
01.12.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0179-z

Weitere Artikel der Ausgabe 4/2014

memo - Magazine of European Medical Oncology 4/2014 Zur Ausgabe

editorial

Angiogenesis